Evidence map›Paper›PMID 29234814›Full record

GuidelineJAMA2017

Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement.

US Preventive Services Task Force, David C Grossman, Susan J Curry, Douglas K Owens, Michael J Barry, Karina W Davidson, Chyke A Doubeni, John W Epling, Alex R Kemper, Alex H Krist and 7 more

Open access · bronzeAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in JAMA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 5 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 5 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Association of Menopausal Hormone Therapy with Risk of Pancreatic Cancer: A Systematic Review and Meta-analysis of Cohort Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative hormone therapy trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. An In Vivo Model of Estrogen Supplementation Concerning the Expression of CaJournal of cardiovascular development and disease · 2024
    Article
  15. Medical expenses and its determinants in female patients with urological disorder.Cost effectiveness and resource allocation : C/E · 2024
    Article
  16. Review
  17. Primary Prevention of Cardiovascular Disease in Women.Methodist DeBakey cardiovascular journal · 2024
    Review
  18. Review
  19. Hormones and Aging: An Endocrine Society Scientific Statement.The Journal of clinical endocrinology and metabolism · 2023
    Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

US Preventive Services Task Force
David C GrossmanKaiser Permanente Washington Health Research Institute, Seattle.
Susan J CurryUniversity of Iowa, Iowa City.
Douglas K OwensVeterans Affairs Palo Alto Health Care System, Palo Alto, California.
Michael J BarryHarvard Medical School, Boston, Massachusetts.
Karina W DavidsonColumbia University, New York, New York.
Chyke A DoubeniUniversity of Pennsylvania, Philadelphia.
John W EplingVirginia Tech Carilion School of Medicine, Roanoke.
Alex R KemperNationwide Children's Hospital, Columbus, Ohio.
Alex H KristFairfax Family Practice Residency, Fairfax, Virginia.
Ann E KurthYale University, New Haven, Connecticut.
C Seth LandefeldUniversity of Alabama at Birmingham.
Carol M MangioneUniversity of California, Los Angeles.
Maureen G PhippsBrown University, Providence, Rhode Island.
Michael SilversteinBoston University, Boston, Massachusetts.
Melissa A SimonNorthwestern University, Evanston, Illinois.
Chien-Wen TsengUniversity of Hawaii, Honolulu.
Harvard University · USNationwide Children's Hospital · USNorthwestern University · USUniversity of California, Los Angeles · USUniversity of Iowa · USBrown University · USCarilion Clinic · USColumbia University · USKaiser Permanente Washington Health Research Institute · USUniversity of Alabama at Birmingham · USUniversity of Hawaiʻi at Mānoa · USVirginia Commonwealth University · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
6 · The paper itself

Abstract

Importance: Menopause occurs at a median age of 51.3 years, and the average US woman who reaches menopause is expected to live another 30 years. The prevalence and incidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and breast cancer, increase with age; however, the excess risk for these conditions that can be attributed to menopause alone is uncertain. Since the publication of findings from the Women's Health Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy has declined. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on the use of menopausal hormone therapy for the primary prevention of chronic conditions. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal women and whether outcomes vary among women in different subgroups or by timing of intervention after menopause. The review did not address hormone therapy for preventing or treating menopausal symptoms. Findings: Although the use of hormone therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, there are also well-documented harms. The USPSTF determined that the magnitude of both the benefits and the harms of hormone therapy in postmenopausal women is small to moderate. Therefore, the USPSTF concluded with moderate certainty that combined estrogen and progestin has no net benefit for the primary prevention of chronic conditions for most postmenopausal women with an intact uterus and that estrogen alone has no net benefit for the primary prevention of chronic conditions for most postmenopausal women who have had a hysterectomy. Conclusions and Recommendation: The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy. (D recommendation).

Indexed as

Hormone Replacement TherapyAdvisory CommitteesAgedEstrogen Replacement TherapyEstrogensFemaleHumansHysterectomyMenopause, PrematureMiddle AgedNoncommunicable DiseasesPostmenopausePrimary PreventionProgestinsUnited StatesEstrogensProgestins

Identifiers

PMID29234814
OpenAlexW2772038101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.